NRAS is altered in 23.15% of melanoma patients [3].

NRAS is an inclusion criterion in 18 clinical trials for melanoma, of which 9 are open and 9 are closed. Of the trials that contain NRAS status and melanoma as inclusion criteria, 11 are phase 1 (6 open), 5 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), and 1 is phase 3 (0 open) [4].

Binimetinib has evidence of efficacy in patients with NRAS mutation in melanoma [4].

NRAS is altered in 2.83% of malignant solid tumor patients [3].

NRAS is an inclusion criterion in 39 clinical trials for malignant solid tumor, of which 27 are open and 12 are closed. Of the trials that contain NRAS status and malignant solid tumor as inclusion criteria, 21 are phase 1 (13 open), 11 are phase 1/phase 2 (8 open), and 7 are phase 2 (6 open) [4].

NRAS is altered in 4.7% of colorectal carcinoma patients [3].

NRAS is an inclusion criterion in 23 clinical trials for colorectal carcinoma, of which 16 are open and 7 are closed. Of the trials that contain NRAS status and colorectal carcinoma as inclusion criteria, 14 are phase 1 (10 open), 4 are phase 1/phase 2 (3 open), and 5 are phase 2 (3 open) [4].

NRAS is altered in 1.14% of non-small cell lung carcinoma patients [3].

NRAS is an inclusion criterion in 21 clinical trials for non-small cell lung carcinoma, of which 15 are open and 6 are closed. Of the trials that contain NRAS status and non-small cell lung carcinoma as inclusion criteria, 14 are phase 1 (11 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (2 open) [4].

NRAS is altered in 9.76% of acute myeloid leukemia patients [3].

NRAS is an inclusion criterion in 12 clinical trials for acute myeloid leukemia, of which 7 are open and 5 are closed. Of the trials that contain NRAS status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (1 open), 4 are phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [4].

NRAS is altered in 3.65% of myelodysplastic syndromes patients [3].

NRAS is an inclusion criterion in 11 clinical trials for myelodysplastic syndromes, of which 7 are open and 4 are closed. Of the trials that contain NRAS status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 4 are phase 1/phase 2 (2 open), and 5 are phase 2 (3 open) [4].

NRAS is altered in 23.35% of chronic myelomonocytic leukemia patients [3].

NRAS is an inclusion criterion in 8 clinical trials for chronic myelomonocytic leukemia, of which 5 are open and 3 are closed. Of the trials that contain NRAS status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 5 are phase 2 (3 open) [4].

NRAS is altered in 4.72% of colorectal adenocarcinoma patients [3].

NRAS is an inclusion criterion in 8 clinical trials for colorectal adenocarcinoma, of which 8 are open and 0 are closed. Of the trials that contain NRAS status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 6 are phase 2 (6 open), and 1 is phase 3 (1 open) [4].

NRAS is altered in 8.5% of multiple myeloma patients [3].

NRAS is an inclusion criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain NRAS status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

NRAS is altered in 1.3% of non-hodgkin lymphoma patients [3].

NRAS is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 3 are open and 2 are closed. Of the trials that contain NRAS status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [4].

NRAS is altered in 0.74% of pancreatic carcinoma patients [3].

NRAS is an inclusion criterion in 5 clinical trials for pancreatic carcinoma, of which 4 are open and 1 is closed. Of the trials that contain NRAS status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [4].

NRAS is altered in 25.73% of cutaneous melanoma patients [3].

NRAS is an inclusion criterion in 4 clinical trials for cutaneous melanoma, of which 4 are open and 0 are closed. Of the trials that contain NRAS status and cutaneous melanoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (1 open) [4].

NRAS is altered in 2.13% of ovarian carcinoma patients [3].

NRAS is an inclusion criterion in 4 clinical trials for ovarian carcinoma, of which 2 are open and 2 are closed. Of the trials that contain NRAS status and ovarian carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 4 clinical trials for pancreatic ductal adenocarcinoma, of which 2 are open and 2 are closed. Of the trials that contain NRAS status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

NRAS is altered in 14.29% of acute lymphoblastic leukemia patients [3].

NRAS is an inclusion criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 1 is closed. Of the trials that contain NRAS status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].

NRAS is altered in 12.38% of thyroid gland carcinoma patients [3].

NRAS is an inclusion criterion in 3 clinical trials for thyroid gland carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NRAS status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

NRAS is altered in 3.13% of cancer patients [3].

NRAS is an inclusion criterion in 3 clinical trials for cancer, of which 1 is open and 2 are closed. Of the trials that contain NRAS status and cancer as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (0 open) [4].

NRAS is altered in 0.87% of glioma patients [3].

NRAS is an inclusion criterion in 3 clinical trials for glioma, of which 3 are open and 0 are closed. Of the trials that contain NRAS status and glioma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

NRAS is an inclusion criterion in 3 clinical trials for neurofibromatosis type 1, of which 2 are open and 1 is closed. Of the trials that contain NRAS status and neurofibromatosis type 1 as inclusion criteria, 3 are phase 2 (2 open) [4].

NRAS is altered in 31.74% of poorly differentiated thyroid gland carcinoma patients [3].

NRAS is an inclusion criterion in 2 clinical trials for poorly differentiated thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

NRAS is altered in 9.64% of secondary acute myeloid leukemia patients [3].

NRAS is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

NRAS is altered in 9.64% of therapy-related acute myeloid leukemia patients [3].

NRAS is an inclusion criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

NRAS is altered in 9.6% of myelodysplastic syndrome with excess blasts-2 patients [3].

NRAS is an inclusion criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain NRAS status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].

NRAS is altered in 9.09% of juvenile myelomonocytic leukemia patients [3].

NRAS is an inclusion criterion in 2 clinical trials for juvenile myelomonocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain NRAS status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 2 (1 open) [4].

NRAS is altered in 3.69% of histiocytic and dendritic cell neoplasm patients [3].

NRAS is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain NRAS status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [4].

NRAS is altered in 1.36% of head and neck squamous cell carcinoma patients [3].

NRAS is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 0 are open and 2 are closed. Of the trials that contain NRAS status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [4].

NRAS is altered in 1.35% of small cell lung carcinoma patients [3].

NRAS is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

NRAS is altered in 0.94% of low grade glioma patients [3].

NRAS is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 0.87% of squamous cell lung carcinoma patients [3].

NRAS is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

NRAS is altered in 0.55% of breast carcinoma patients [3].

NRAS is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NRAS status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 57.14% of chronic myelomonocytic leukemia-2 patients [3].

NRAS is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-2, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 20.0% of chronic myelomonocytic leukemia-0 patients [3].

NRAS is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-0, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and chronic myelomonocytic leukemia-0 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 19.86% of thyroid gland undifferentiated (anaplastic) carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is altered in 19.74% of embryonal rhabdomyosarcoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 15.5% of thyroid gland follicular carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is altered in 14.29% of T-cell acute lymphoblastic leukemia patients [3].

NRAS is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 14.37% of mucosal melanoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is altered in 13.51% of chronic myelomonocytic leukemia-1 patients [3].

NRAS is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia-1, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and chronic myelomonocytic leukemia-1 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 9.57% of low grade ovarian serous adenocarcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is altered in 8.31% of thyroid gland papillary carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is altered in 7.91% of refractory anemia with excess blasts patients [3].

NRAS is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 2 (0 open) [4].

NRAS is altered in 7.61% of myeloid neoplasm patients [3].

NRAS is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is altered in 6.06% of myelodysplastic/myeloproliferative neoplasm, unclassifiable patients [3].

NRAS is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is altered in 5.14% of rectal carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and rectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is altered in 4.87% of colon carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for colon carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and colon carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 3.19% of malignant peripheral nerve sheath tumor patients [3].

NRAS is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 3.19% of cholangiocarcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is altered in 3.04% of endometrial carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 2.78% of mantle cell lymphoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

NRAS is altered in 2.82% of secondary myelodysplastic syndrome patients [3].

NRAS is an inclusion criterion in 1 clinical trial for secondary myelodysplastic syndrome, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (0 open) [4].

NRAS is altered in 2.82% of therapy-related myelodysplastic syndrome patients [3].

NRAS is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is altered in 3.02% of lymphoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is altered in 2.31% of neuronal and mixed neuronal-glial tumors patients [3].

NRAS is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 2.25% of ganglioglioma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 1.79% of soft tissue sarcoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 1.51% of bladder carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is altered in 2.0% of esophageal carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is altered in 1.38% of sarcoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is altered in 1.08% of thymic carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is altered in 1.13% of lung adenocarcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and lung adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 1.15% of lung carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is altered in 1.01% of uveal melanoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is altered in 1.08% of head and neck carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is altered in 0.95% of diffuse glioma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 1.07% of squamous cell carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is altered in 0.85% of chronic myeloid leukemia patients [3].

NRAS is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 1.12% of adenocarcinoma of the gastroesophageal junction patients [3].

NRAS is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (0 open) [4].

NRAS is altered in 0.93% of glioblastoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is altered in 1.34% of neuroblastoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 0.79% of astrocytic tumor patients [3].

NRAS is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is altered in 0.7% of hepatocellular carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

NRAS is altered in 0.72% of pancreatic adenocarcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is altered in 0.75% of diffuse large B-cell lymphoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

NRAS is altered in 0.43% of anaplastic astrocytoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

NRAS is altered in 0.44% of gastric adenocarcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

NRAS is altered in 0.44% of gastric carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is altered in 0.41% of prostate carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

NRAS is altered in 0.13% of renal cell carcinoma patients [3].

NRAS is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

NRAS is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].